国际医药卫生导报2013，Vol.19Issue(13)：1987-1989,3.DOI:10.3760/cma.j.issn.1007-1245.2013.13.037
急性髓系白血病CD34、CD123抗原和P170蛋白表达与预后关系的研究
Assoication of expressions of CD34, CD123, and P170 with prognosis in acute myelocytic leukemia
廖建军 1张健 2黄继贤 1韦湘 1谢治军1
作者信息
- 1. 512026韶关,汕头大学医学院附属粤北人民医院血液内科
- 2. 512026韶关,汕头大学医学院附属粤北人民医院检验科
- 折叠
摘要
Abstract
Objective To explore the association of expressions of CD34,CD123,and P170 with prognosis in acute myelocytic leukemia (AML).Methods 28 patients with AML who had been hospitalized during the period of October 2011 to October 2012 received chemotherapy.Expressions of CD34,CD123,and P170 were detected by flow cytometry before and after treatment.The clinical efficacy of treatment for AML was analyzed and statistically compared by using the indexes of complete remission (CR) and non-remission (NR).Results The positive rate of CD34,CD123,or P170 was higher in patients with recurrence than patients with primary treatment,with a significant difference between the two groups (P＜0.05).There were three patients with NR and no one with CR when CD34 and CD123 antigens and P170 protein were simultaneously positive,with a statistical difference (P＜0.05) as compared with other CR groups.Conclusions The rate of complete remission for AML is decreased significantly,when CD34 and CD123 antigens and P170 protein are co-expressed.Co-expression of CD34 and CD123 antigens and P170 protein can be used as a predicting index for prognosis of AML,and provides a valuable support for chemotherapy for AML and for predicting prognosis.关键词
急性髓系白血病/CD34抗原/CD123抗原/P170蛋白/预后Key words
Acute myelocytic leukemia/CD34 antigen/CD123 antigen/P170 protein/Prognosis引用本文复制引用
廖建军,张健,黄继贤,韦湘,谢治军..急性髓系白血病CD34、CD123抗原和P170蛋白表达与预后关系的研究[J].国际医药卫生导报,2013,19(13):1987-1989,3.
